Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Q32 Bio ( (QTTB) ) just unveiled an announcement.
On June 20, 2025, Jason Campagna, M.D., Ph.D., resigned as Chief Medical Officer of Q32 Bio, effective July 9, 2025, and Adrien Sipos, M.D., Ph.D., was appointed as Interim Chief Medical Officer. Dr. Sipos, an experienced immunologist, will contribute to advancing the SIGNAL-AA Phase 2a clinical trial for bempikibart, a novel treatment for alopecia areata, which shows promising potential for patients needing new treatment options.
The most recent analyst rating on (QTTB) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Q32 Bio stock, see the QTTB Stock Forecast page.
Spark’s Take on QTTB Stock
According to Spark, TipRanks’ AI Analyst, QTTB is a Neutral.
Q32 Bio’s overall stock score is low due to significant financial instability, negative revenue, and ongoing losses. The technical analysis shows mixed signals, while the valuation is unattractive with a negative P/E ratio and no dividends. These factors highlight the company’s current financial and operational challenges, suggesting a need for strategic changes to improve its financial health.
To see Spark’s full report on QTTB stock, click here.
More about Q32 Bio
Q32 Bio is a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. The company is advancing bempikibart, a fully human anti-IL-7Rα antibody, for the treatment of alopecia areata in an ongoing Phase 2 program.
Average Trading Volume: 154,506
Technical Sentiment Signal: Sell
Current Market Cap: $18.66M
Find detailed analytics on QTTB stock on TipRanks’ Stock Analysis page.